AMT-116

Phase 2Small molecule

AMT-116 is one of 90 small molecule programs targeting Advanced Non-Small Cell Lung Cancer (NSCLC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Non-Small Cell Lung Cancer (NSCLC)Recruiting

NSCLC (advanced Non-Small Cell Lung Cancer)Not yet recruiting

Patients With Advanced Solid TumorsRecruiting

Patients With Solid TumorsRecruiting

Advanced Non-Small Cell Lung Cancer (NSCLC)Preclinical

Recruiting

NSCLC (advanced Non-Small Cell Lung Cancer)Preclinical

Not yet recruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Patients With Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

249 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

20 2

Eloxatin

Teva

Phase 2

9 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

23 4

Tecentriq

Roche

Phase 2

4 5

Camptosar

Pfizer

Phase 2

4 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

15 7

Erbitux

IImclone

Phase 2

10 8

Tuoyi

CCoherus Oncology, Inc.

Phase 2

9 9

Lazcluze

Johnson & Johnson

Phase 2

1 10

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT05725291

Phase 1/2Recruiting

Patients With Solid Tumors

NCT06782334

Q4 2027

PreclinicalRecruiting

Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT07590531

Q4 2028

PreclinicalNot yet recruiting

NSCLC (advanced Non-Small Cell Lung Cancer)

NCT07718737

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

AMT-116 in Patients With Advanced Solid Tumors

Recruiting·MMultitude Therapeutics Inc.·Phase 1·NCT05725291·80 enrolled

Patients With Solid Tumors1 trial

AMT-116 in Patients with Solid Tumors

Recruiting·MMultitude Therapeutics Inc.·Phase 1/2·NCT06782334·144 enrolled

NSCLC (Advanced Non-small Cell Lung Cancer)1 trial

Open-Label, Global, Multicenter, Randomized, Phase 2/3 Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Not yet recruiting·MMultitude Therapeutics Inc.·Preclinical·NCT07718737·512 enrolled

Advanced Non-Small Cell Lung Cancer (NSCLC)1 trial

An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivonescimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting·MMultitude Therapeutics Inc.·Preclinical·NCT07590531·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AMT-116. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMT-116 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMT-116. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Multitude Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMultitude Therapeutics Inc.

AMT-116

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Patients With Solid Tumors1 trial

NSCLC (Advanced Non-small Cell Lung Cancer)1 trial

Advanced Non-Small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News